Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Kenvue Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $33.0B | |
|---|---|---|
| Revenue (ttm) | 15.4B | |
| Net income (ttm) | 1.7B | |
| EPS (ttm) | $0.85 | |
| Shares out | 1.9B | |
| P/E (trailing) | 22.7x | |
| P/E (forward) | 14.7x | |
| Dividend | $0.84 (4.34%) | |
| Volume | 6,839,244 | |
| Beta | 0.45 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2022-01-02 | 2023-01-01 | 2023-12-31 | 2024-12-29 | 2025-12-28 | Trend |
| Revenue | $15.05B | $14.95B | $15.44B | $15.46B | $15.12B | +0.1% |
| Gross profit | $8.42B | $8.29B | $8.64B | $8.96B | $8.79B | +1.1% |
| Operating income | $2.92B | $2.68B | $2.51B | $1.84B | $2.41B | -4.6% |
| Net income | $2.08B | $2.06B | $1.66B | $1.03B | $1.47B | -8.3% |
| EPS (diluted) | $1.21 | $1.20 | $0.90 | $0.54 | $0.76 | -11.0% |
| EBITDA | $3.66B | $3.28B | $3.18B | $2.47B | $2.94B | -5.3% |
| R&D | $355.0M | $375.0M | $399.0M | $408.0M | $382.0M | +1.8% |
| SG&A | $5.48B | $5.63B | $6.14B | $6.33B | $6.09B | +2.6% |
Recent company headlines from major financial publishers.
The base outcome assumes steady consumer replenishment in non-discretionary over-the-counter healthcare categories, maintaining predictable top-line progression and stable operating margins. Steady channel execution preserves shelf placement across mass retail partners while cash generation covers regular dividends and scheduled debt maturities. This modal path projects a target of $18.17 with an estimated probability of 55.0%, delivering an implied return of 5.6% against $17.20 (as of 2026-10-02).
In the bull outcome, brand reinvestment and strong clinical positioning accelerate organic revenue expansion across Self Care and international territories. Operating efficiencies expand operating margins toward peer benchmark levels, unlocking superior cash generation. At a target value of $23.53 carrying an estimated probability of 20.0%, this path offers an implied return of 36.8% relative to $17.20 (as of 2026-10-02).
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 6.2% | $20.0 | $20.7 | $21.4 | $22.2 | $23.1 |
| 6.7% | $18.5 | $19.0 | $19.6 | $20.3 | $21.0 |
| 7.2% | $17.3 | $17.7 | $18.2 | $18.7 | $19.3 |
| 7.7% | $16.2 | $16.6 | $16.9 | $17.4 | $17.8 |
| 8.2% | $15.3 | $15.6 | $15.9 | $16.2 | $16.6 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
